BioCentury | Apr 17, 2020
Emerging Company Profile

Rgenta: enhancing interactions between RNA and RNA-binding proteins

...Therapeutics Inc. have platforms for discovering small molecules that bind target RNA molecules. Another company, Twentyeight-Seven Therapeutics...
BioCentury | Jul 11, 2019
Emerging Company Profile

Twentyeight-Seven’s bet on RNA-binding proteins

...lot faster, and we may be out raising money in next three years.” COMPANY PROFILE Twentyeight-Seven Therapeutics...
...Arrakis Therapeutics Inc., Waltham, Mass. Expansion Therapeutics Inc., San Diego, Calif. Ribometrix Inc., Durham, N.C. Twentyeight-Seven Therapeutics...
...myelocytomatosis viral oncogene homolog SNRP200 - Small nuclear ribonucleoprotein U5 subunit 200 Karen Tkach Tuzman, Associate Editor Twentyeight-Seven Therapeutics Lin-28...
BioCentury | May 10, 2019
Financial News

May 10 Financial Quick Takes: Intercept raises over $400M; plus 28-7, LunaPBC

...existing shareholder Samsara BioCapital. Sofinnova Partners, OUP top off 28-7’s A round Non-coding RNA company Twentyeight-Seven Therapeutics...
BioCentury | Sep 7, 2018
Financial News

Non-coding RNA company Twentyeight-Seven debuts with $65M

...is also the CEO of Syndax Pharmaceuticals Inc. (NASDAQ:SNDX). Twentyeight-Seven Therapeutics Inc., Cambridge, Mass. Elizabeth S. Eaton non-coding RNA Twentyeight-Seven Therapeutics...
BioCentury | Sep 6, 2018
Financial News

Non-coding RNA company Twentyeight-Seven debuts with $65M

...joined Twentyeight-Seven's board. Morrison is also the CEO of Syndax Pharmaceuticals Inc. (NASDAQ:SNDX). Elizabeth S. Eaton non-coding RNA Twentyeight-Seven Therapeutics...
Items per page:
1 - 5 of 5
BioCentury | Apr 17, 2020
Emerging Company Profile

Rgenta: enhancing interactions between RNA and RNA-binding proteins

...Therapeutics Inc. have platforms for discovering small molecules that bind target RNA molecules. Another company, Twentyeight-Seven Therapeutics...
BioCentury | Jul 11, 2019
Emerging Company Profile

Twentyeight-Seven’s bet on RNA-binding proteins

...lot faster, and we may be out raising money in next three years.” COMPANY PROFILE Twentyeight-Seven Therapeutics...
...Arrakis Therapeutics Inc., Waltham, Mass. Expansion Therapeutics Inc., San Diego, Calif. Ribometrix Inc., Durham, N.C. Twentyeight-Seven Therapeutics...
...myelocytomatosis viral oncogene homolog SNRP200 - Small nuclear ribonucleoprotein U5 subunit 200 Karen Tkach Tuzman, Associate Editor Twentyeight-Seven Therapeutics Lin-28...
BioCentury | May 10, 2019
Financial News

May 10 Financial Quick Takes: Intercept raises over $400M; plus 28-7, LunaPBC

...existing shareholder Samsara BioCapital. Sofinnova Partners, OUP top off 28-7’s A round Non-coding RNA company Twentyeight-Seven Therapeutics...
BioCentury | Sep 7, 2018
Financial News

Non-coding RNA company Twentyeight-Seven debuts with $65M

...is also the CEO of Syndax Pharmaceuticals Inc. (NASDAQ:SNDX). Twentyeight-Seven Therapeutics Inc., Cambridge, Mass. Elizabeth S. Eaton non-coding RNA Twentyeight-Seven Therapeutics...
BioCentury | Sep 6, 2018
Financial News

Non-coding RNA company Twentyeight-Seven debuts with $65M

...joined Twentyeight-Seven's board. Morrison is also the CEO of Syndax Pharmaceuticals Inc. (NASDAQ:SNDX). Elizabeth S. Eaton non-coding RNA Twentyeight-Seven Therapeutics...
Items per page:
1 - 5 of 5